0001365618-16-000007.txt : 20160411 0001365618-16-000007.hdr.sgml : 20160411 20160411163306 ACCESSION NUMBER: 0001365618-16-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160407 FILED AS OF DATE: 20160411 DATE AS OF CHANGE: 20160411 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anacor Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001411158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 251854385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1020 E. MEADOW CIRCLE CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 650-543-7500 MAIL ADDRESS: STREET 1: 1020 E. MEADOW CIRCLE CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Anacor Pharmaceuticals Inc DATE OF NAME CHANGE: 20070830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hove Anders D CENTRAL INDEX KEY: 0001365618 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34973 FILM NUMBER: 161565440 MAIL ADDRESS: STREET 1: 30 ROCKEFELLER PLAZA, SUITE 5508 CITY: NEW YORK STATE: NY ZIP: 10112 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-04-07 0001411158 Anacor Pharmaceuticals, Inc. ANAC 0001365618 Hove Anders D C/O VENROCK 3340 HILLVIEW AVE. PALO ALTO CA 94304 1 0 0 0 Common Stock 2016-04-07 4 S 0 102760 70.33 D 222775 I By Funds and LLC's Common Stock 2016-04-07 4 S 0 99981 71.44 D 122794 I By Funds and LLC's Common Stock 2016-04-07 4 S 0 13000 72.15 D 109794 I By Funds and LLC's Common Stock 2016-04-07 4 S 0 2272 73.29 D 107522 I By Funds and LLC's Common Stock 2016-04-07 4 S 0 200 74.13 D 107322 I By Funds and LLC's Common Stock 2016-04-07 4 S 0 6820 75.57 D 100502 I By Funds and LLC's Common Stock 2016-04-08 4 S 0 3868 70.05 D 96634 I By Funds and LLC's Common Stock 2016-04-08 4 S 0 400 71.40 D 96234 I By Funds and LLC's Common Stock 33886 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Venrock Healthcare Capital Partners, L.P. ("VHCP"), VHCP Co-Investment Holdings, LLC ("VHCP Co-Invest"), Venrock Associates IV, L.P. ("VA4"), Venrock Partners, L.P. ("VP") and Venrock Entreprenerus Fund IV, L.P. ("VEF4") on March 16, 2016. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) - (18) to this Form 4. The shares are held as follows: 102,931 shares held by VA4, 20,991 shares held by VP, 2,529 shares held by VEF4, 81,429 shares held by VHCP and 14,895 shares held by VHCP Co-Invest. Venrock Management IV, LLC ("VM4"), Venrock Partners Management, LLC ("VPM") and VEF Management IV, LLC ("VEFM4") are the sole general partners of VA4, VP and VEF4, respectively, and may be deemed to beneficially own these shares. VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. Anders Hove is a member of VM4, VPM and VEFM4 and a managing member of VHCP Management. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP, VEF4, VHCP, VHCP Co-Invest, VM4, VPM, VEFM4 and VHCP Management except to the extent of his indirect pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive. The shares are held as follows: 56,736 shares held by VA4, 11,570 shares held by VP, 1,394 shares held by VEF4, 44,884 shares held by VHCP and 8,210 shares held by VHCP Co-Invest. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.96, inclusive. The shares are held as follows: 50,729 shares held by VA4, 10,345 shares held by VP, 1,247 shares held by VEF4, 40,132 shares held by VHCP and 7,341 shares held by VHCP Co-Invest. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.03 to $73.88, inclusive. The shares are held as follows: 49,679 shares held by VA4, 10,131 shares held by VP, 1,221 shares held by VEF4, 39,302 shares held by VHCP and 7,189 shares held by VHCP Co-Invest. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.11 to $74.16, inclusive. The shares are held as follows: 49,587 shares held by VA4, 10,113 shares held by VP, 1,218 shares held by VEF4, 39,228 shares held by VHCP and 7,176 shares held by VHCP Co-Invest. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.17 to $75.84, inclusive. The shares are held as follows: 46,436 shares held by VA4, 9,470 shares held by VP, 1,141 shares held by VEF4, 36,735 shares held by VHCP and 6,720 shares held by VHCP Co-Invest. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. The shares are held as follows: 44,649 shares held by VA4, 9,106 shares held by VP, 1,097 shares held by VEF4, 35,321 shares held by VHCP and 6,461 shares held by VHCP Co-Invest. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.39 to $71.41, inclusive. The shares are held as follows: 44,464 shares held by VA4, 9,068 shares held by VP, 1,092 shares held by VEF4, 35,175 shares held by VHCP and 6,435 shares held by VHCP Co-Invest. The reporting person is a member of VR Management, LLC (the "Management Company"). Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold an aggregate of 794 of the reported securities for the sole benefit of the Management Company (the "Management Company Shares"). The Management Company may be deemed the indirect beneficial owner of the Management Company Shares, and the reporting person may be deemed the indirect beneficial owner of the Management Company Shares through his interest in the Management Company. The reporting person disclaims beneficial ownership of the Management Company Shares except to the extent of his indirect pecuniary interest therein. /s/ Anders D. Hove 2016-04-11